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BACKGROUND AND PURPOSE
Indoleamine 2,3-dioxygenase 1 (IDO1) is emerging as an important new therapeutic target for treatment of malignant tumours
characterized by dysregulated tryptophan metabolism. However, the antitumour efficacy of existing small-molecule inhibitors of
IDO1 is still unsatisfactory and the underlying mechanism remains largely undefined. Hence, we discovered a novel potent small-
molecule inhibitor of IDO1, LW106, and studied its antitumour effects and the underlying mechanisms in two tumour models.
EXPERIMENTAL APPROACH
C57BL6 mice, athymic nude mice or Ido1/ mice were inoculated with IDO1-expressing and -nonexpressing tumour cells and
treated with vehicle, epacadostat or increasing doses of LW106. Xenografted tumours, plasma, spleens and other vital organs
were harvested and subjected to kynurenine/tryptophan measurement and flow cytometric, histological and immunohisto-
chemical analyses.
KEY RESULTS
LW106 dose-dependently inhibited the outgrowth of xenografted tumours that were inoculated in C57BL6 mice but not nude
mice or Ido1/ mice, showing a stronger antitumour efficacy than epacadostat, an existing IDO1 inhibitor. LW106 substantially
elevated intratumoural infiltration of proliferative Teff cells, while reducing recruitment of proliferative Treg cells and
non-haematopoietic stromal cells such as endothelial cells and cancer-associated fibroblasts. LW106 treatment resulted in a
reduced subpopulation of cancer stem cells (CSCs) in xenografted tumours in which fewer proliferative/invasive tumour cells and
more apoptotic tumour cells were observed.
CONCLUSIONS AND IMPLICATIONS
LW106 inhibits tumour outgrowth by limiting stroma-immune crosstalk and CSC enrichment in the tumour micro-environment.
LW106 has potential as a immunotherapeutic agent for use in combination with immune checkpoint inhibitors and (or)
chemotherapeutic drugs for cancer treatment.
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Introduction
The intracellular enzyme indoleamine 2,3-dioxygenase 1
(IDO1) is a monomeric oxidoreductase that catalyses the first
and rate-limiting step in tryptophan degradation, leading
to subsequent production of bioactive tryptophan metabolites
kynurenine (Sono and Hayaishi, 1980; Botting, 1995; Sono
et al., 1996). IDO1 has been proposed as a potential contributor
to immunosuppression, tolerance and tumour escape from the
immune system (Munn et al., 1999; Munn and Mellor, 2004,
2007; Prendergast, 2008). IDO1-mediated depletion of trypto-
phan and production of kynurenine can lead to an immunosup-
pressive tumour micro-environment (TME), in which the
proliferation of effector T cells is inhibited while suppressive
populations of regulatory T cells are activated (Fallarino et al.,
2002; Frumento et al., 2002; Munn and Mellor, 2004, 2007).
The presence of IDO1 in TME has been shown to correlate with
tumour progression, invasion andmetastasis and can be used as
an independent prognostic marker of survival in various types
of cancers (Brandacher et al., 2006; Polak et al., 2007; Ino et al.,
2008; Pan et al., 2008). It has been demonstrated that IDO1 is
produced mainly by the tumour cells and host-derived
immune cells such as dendritic cells (DCs) and macrophages
that are recruited to TME by the tumour (Munn et al., 1999;
Munn et al., 2002).
The TME is the cellular micro-environment in which the tu-
mour exists, which includes tumour-infiltrating immune cells
(e.g. T cells, DCs and macrophages) and non-haematopoietic
stromal cells such as cancer-associated fibroblasts (CAFs), endo-
thelial cells (ECs) and pericytes, along with the extracellular ma-
trix (ECM) and inflammatory mediators they secrete (Coussen
and Werb, 2002; Johansson et al., 2008; Hanahan and
Weinberg, 2011; Hanahan and Coussens, 2012; Turley et al.,
2015). There is emerging evidence suggesting that the crosstalk
(interaction) between the stromal compartment and immune
system within the TME can influence tumour growth, metasta-
sis and chemoresistance (Joyce and Pollard, 2009; Holmgaard
et al., 2013). CAFs, the predominant stromal cells, together with
ECs and pericytes, enhance the proliferation, extravasation and
infiltration of regulatory T cells and reduce the trafficking of pro-
liferative effector T cells to the tumour bed, which can hinder
antitumour immune responses and promote tumour progres-
sion (Castermans and Griffioen, 2007; Buckanovich et al.,
2008; Tan et al., 2011; Feig et al., 2013; Turley et al., 2015).
ECM, the non-cellular component in the TME, may also sup-
press antitumour immune responses and thus support tumour
growth by limiting T cell motility (Provenzano et al., 2012;
Salmon et al., 2012; Caruana et al., 2015; Turley et al., 2015).
However, the stromal immunoregulation in the TME is not uni-
directional. A growing body of evidence now exists to suggest
that the infiltrating immune cells can actively shape the stromal
milieu in the TME, thus highlighting a considerable level of
crosstalk (interaction) between stromal and immune cells
(Beatty et al., 2011; Lu et al., 2011; Coussens et al., 2013; Turley
et al., 2015). Stromal cells and their associated ECM are now
known to play an essential role in controlling the expansion
of cancer stem cells (CSCs), a population of tumour cells that
possess the defining features of clonogenicity and self-renewal,
and CSCs are thought to have a critical role in tumour progres-
sion, metastasis and chemoresistance (Bhowmich et al., 2004;
Turley et al., 2015; Ni et al., 2016).
It is still unclear whether tumour cell-derived IDO1 con-
tributes to tumour progression in patients (Holmgaard et al.,
2013). In the present study, we perform a bioinformatic anal-
ysis of the relationship between tumour cell-derived IDO1
expression levels and survival rates in patients using an on-
line tool (http://kmplot.com/analysis/), which is capable of
assessing the effect of 54 675 genes on survival using 10 461
cancer samples, including 5143 breast, 1816 ovarian, 2437
lung and 1065 gastric cancer patients with a mean follow-
up of 69, 40, 49 and 33 months respectively (Gyorffy et al.,
2010, 2012, 2013; Szasz et al., 2016).
IDO1 is emerging as an important new therapeutic target
for the treatment of cancer, and three small-molecule inhibitors
of IDO1, 1-methyl-tryptophan (1-MT), NLG919 and
epacadostat are currently in clinical trials for treatment of
non-small cell lung cancer (NSCLC), melanoma and other
types of cancer (Cady and Sono, 1991; Liu et al., 2010; Jack-
son et al., 2013). However, the antitumour efficacy of these
existing inhibitors is still unsatisfactory and the underlying
mechanism remains largely undefined. In the present study,
we describe the discovery and characterization of LW106, a
structurally novel small-molecule inhibitor of IDO1. We
found that LW106 displays a stronger antitumour efficacy as
compared with epacadostat, and further revealed that
LW106 inhibits tumour growth by limiting the interaction
(crosstalk) between the stromal compartment and the im-
mune system and the enrichment of CSCs in the TME. Our
data suggest that LW106 can be further developed as a poten-
tial immunotherapeutic agent for cancer treatment.
Methods
Mice and human samples
Eight-week-old male C57BL/6 mice and athymic nude mice
were purchased from Qinglongshan Animal Facility in Nan-
jing, China. Congenic Ido1/ mice on a C57BL/6 strain
background were obtained from the Jackson Laboratory. All
mice were housed under standard specific-pathogen-free con-
ditions, and all research involving animals strictly complied
with protocols approved by the Animal Welfare and Ethics
Committee (China Pharmaceutical University). Animal
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studies are reported in compliance with the ARRIVE guide-
lines (Kilkenny et al., 2010; McGrath and Lilley, 2015). Hu-
man peripheral blood mononuclear cells (PBMCs) from
healthy volunteers were purchased from Nanjing Red Cross
Blood Centre.
Cell culture
HeLa ovarian carcinoma cells, Lewis lung carcinoma cells and
B16F10 melanoma cells were purchased from ATCC (Rocke-
feller, MD, USA) and grown in DMEM supplemented with
10% heat-inactivated FBS and 1% penicillin/streptomycin
(Invitrogen, Carlsbad, CA, USA). Cells were tested for myco-
plasma contamination each month, and only mycoplasma-
negative cells were used. Short tandem repeat DNA finger-
printing analysis was performed in 2016 for authentication
of these cells.
Tumour formation and drug treatment
Tumour xenograft experiments were performed in 8- to 10-
week-old mice challenged s.c. with 6 × 105 Lewis tumour cells
or 2 × 105 B16F10 melanoma cells. Mice were randomly di-
vided into five groups and injected i.p. daily with vehicle
alone, LW106 at doses of 20, 40 and 80 mg·kg1 or
epacadostat at 80 mg·kg1 at day 6 following initial tumour
cell engraftment until termination of the experiment. All
compounds were dissolved freshly in sodium citrate buffer
prior to each experiment. Tumour volume was measured ev-
ery 2 days at day 3 post-tumour inoculation using the for-
mula V = π × length × width2/6. Tumours were harvested,
weighed and subjected to further analysis.
FACS analysis
For the T cell assay, xenografted tumours were dissected,
minced into small pieces and digested for 45 min at 37°C in
1X HBSS buffer containing 2% FBS, 1 mg·mL1 collagenase I
(Sigma-Aldrich, St Louis, Missouri, USA) and 0.5 mg·mL1
dispase (Invitrogen), followed by further digestion in 10-
μg·mL1 DNase (Invitrogen) for 45 min, and 0.64% ammo-
nium chloride (STEMCELL Technologies, Vancouver,
Canada) for 5 min at 37°C; Spleens from tumour-bearing
mice were dissected into pieces and dissociated mechanically
in D-Hank’s buffer (Invitrogen) for 10 min on ice. Cells were
filtered through a 70 μm cell strainer (BD Biosciences, Frank-
lin Lakes, NJ, USA), resuspended in 1X HBSS buffer contain-
ing 2% FBS and subjected to a gradient centrifugation in
Ficoll-Pague (Sigma-Aldrich). Purified lymphocytes were
stained using a fixation and permeabilization kit
(eBioscience, San Diego, CA, USA) and analysed by FACS
analysis to detect the expression of CD45, CD4, CD8, Foxp3
(all from Biolegend, San Diego, CA, USA) and Ki67 (Cell Sig-
naling, Danvers, MA, USA). For the CSC assay, xenografted
tumours were dissected into pieces and dissociated enzy-
matically as described above. Cells were incubated with an
antibody cocktail containing CD31, CD45 and Ter119
(STEMCELL Technologies), a secondary biotin-labelled anti-
body cocktail (STEMCELL Technologies) and magnetic
beads (15 min each). The unbound cells (LIN) were col-
lected and labelled with APC-CD44 or PE-CD144 (both from
BD Biosciences) for 30 min at 4°C, followed by DAPI stain-
ing for 5 min at 4°C. Cells were washed extensively and sub-
jected to an aldehyde dehydrogenase (ALDH) activity assay
using a kit from STEMCELL Technologies, according to
the manufacturer’s instructions. The labelled cells were
subjected to FACS analysis to detect ALDH activity and
the expression of CD133 and CD44.
Lymphocyte and DC co-culture
Lymphocyte and DC co-cultures were performed as described
previously with a slightmodification (Liu et al., 2010). PBMCs
from healthy volunteers were subjected to centrifugal elutria-
tion to obtain monocytes and lymphocytes. The purified
monocytes were treated with 10 ng·mL1 human recombinant
IL-4 (R & D Systems, Minneapolis, MN, USA) and 40 ng·mL1
human recombinant GM-CSF (R & D Systems) for 5 days, and
the floating and loosely attached cells (i.e. IDO1 immature
DCs) were harvested. IDO1+ mature DCs were obtained by
treating immature DCs with 50 ng·mL1 human recombinant
IFN-γ (Peprotech, Rocky Hill, NJ, USA) and 1 μg·mL1 LPS
(Sigma-Aldrich) for an additional 2 days. IDO1+ mature DCs or
IDO1 immature DCs were co-cultured with purified lympho-
cytes in the presence of vehicle, LW106 or epacadostat for 2-
days. Cells were harvested, stained with anti-CD8 antibody
(Biolegend) and subjected to FACS analysis.
Tumoursphere assay
FACS-sorted single cells were plated in ultralow-attachment
plates (2 × 104 cells per well; Corning, Corning, NY, USA)
with serum-free DMEM/F12 medium (Invitrogen), supple-
mented with B27 (Invitrogen), 20 ng·mL1 EGF, 20 ng·mL1
bFGF (R & D Systems) and 4 mg·mL1 heparin (Sigma, St
Louis, Missouri, USA). Tumourspheres were counted 7 days
after plating.
Tryptophan/kynurenine measurement
Tryptophan/kynurenine measurements were performed as
described previously with slight modifications (Liu et al.,
2010). To measure IDO1 enzyme activity in vitro, HeLa cells
were stimulated with 50 ng·mL1 human recombinant
IFN-γ for 48 h, and conditioned media were collected, centri-
fuged to remove cell debris and stored at 20°C for further
use. To measure IDO1 enzyme activity in vivo, blood and tu-
mours from vehicle- or drug-treated mice were collected and
stored at 20°C for further use. Tumours were homogenized
in three volumes of normal saline with 0.1% formic acid.
Following protein-precipitation extraction with methanol,
supernatants of conditioned media, plasma and tumour
homogenates were collected and 20 μL of the supernatants
were subjected to LC/MS/MS analysis. Aqueous standards




For histology, tissues were fixed in 4% paraformaldehyde, em-
bedded in paraffin and sectioned, followed by haematoxylin
and eosin (H&E) staining. For immunohistochemical assays,
paraffin-embedded sections were deparaffinized, rehydrated
and subjected to antigen heat retrieval with citric buffer,
pH 6.0 (Vector Laboratories, Burlingame, CA, USA). The sec-
tions were treated with 0.5% H2O2 (Sigma-Aldrich) for
10 min at room temperature and further incubated in
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blocking buffer (5% goat serum in PBS) supplemented with
primary antibodies against cleaved caspase 3 (Cell Signal-
ing), Ki67 (Abcam, Cambridge, UK) and p-Histone H3 (Cell
Signaling) overnight at 4°C, followed by incubation with bio-
tinylated goat anti-rabbit secondary antibody (Vector Laborato-
ries) at room temperature for 1 h. A standard ABC kit and DAB
(Vector Laboratories) were used for the detection of HRP
activity. Sections were counterstained with haematoxylin,
dehydrated and mounted. In some experiments, sections were
incubated in blocking buffer (5% goat serum in PBS) contain-
ing primary antibodies against CD31, α-smooth muscle actin
(α-SMA) (both from Abcam), K14 (Biolegend) and CD8
(Biolegend) overnight at 4°C, followed by incubation with
goat anti-rat Alexa 488, goat anti-rabbit Alexa 488 and goat
anti-rabbit Alexa 594 secondary antibodies (all from
Invitrogen) for 1 h at room temperature. Sections were stained
with DAPI for 5–10 min at room temperature and mounted
for confocal microscopy.
Immunoblotting assay
Cells were harvested and lysed in RIPA buffer (Thermo Scien-
tific) containing proteinase inhibitor cocktail (Thermo Scien-
tific) on ice for 20 min, followed by centrifugation for 20 min
at 4°C, 14 000 g. The supernatants were collected and sub-
jected to immunoblotting assay using anti-IDO1 antibody
(Merck).
Cell survival assay
Tumour cells were seeded in 12-well culture plates and treated
with vehicle or the indicated compounds at different concen-
trations for 2 days. Cells were harvested, resuspended in
trypan blue staining buffer (containing 0.04% trypan blue,
Thermo Fisher) and cultured for 3 min at room temperature.
Live cells (i.e. cells that excluded trypan blue) were instantly
counted under light microscope, and survival rates of cells
were calculated.
Kaplan–Meier survival analysis
Overall survival (OS), post-progression survival (PPS) and
distant-metastasis-free survival (DMFS) rates were assessed
in lung cancer patients (with indicated subtypes; Gyorffy
et al., 2010), ovarian cancer patients (Gyorffy et al., 2012),
breast cancer patients (Gyorffy et al., 2013) and gastric cancer
patients (Szasz et al., 2016). The patients were divided into
‘high’ and ‘low’ groups by median IDO1 expression. All other
parameters were left as default settings.
Statistical analysis
All results wherever necessary were subjected to statistical
analysis. Data are presented as mean ± SEM. Statistical analy-
sis was performed as described in each corresponding figure
legend. Sample sizes are shown in each corresponding figure
legend. P < 0.05 was considered significant. The data and sta-
tistical analysis comply with the recommendations on exper-
imental design and analysis in pharmacology (Curtis et al.,
2015).
Chemical compounds
LW106 (MW: 245; Figure S1) was synthesized at the Depart-
ment of Medicinal Chemistry, School of Pharmacy, China
Pharmaceutical University, and the purity was no less than
99%. Using the binding model of the lead compound 62 with
IDO1 (PDB code: 2D0T) by molecular docking, we probed the
active site and discovered more potent IDO inhibitors based
on 62. It was observed oximido of 62 could interact with
haem 7-propionic acid to form a conserved hydrogen con-
tributing greatly to the strong protein occupancy. The
oxadiazole of 62 is directed towards the backup hydrophobic
pocket (Arg231, Phe226) and forms a strong cationπ interac-
tion with Arg231 of the protein. While the benzyl group of
62 is oriented towards the small hydrophobic pocket, away
from the haem iron and thus lacking any specific interaction
with the protein. We hypothesized that replacement of the
imine (62) with heterocycles (LW106) to occupy the deep
space and stabilize the conformation of the compound
might have a favourable contribution to the affinity im-
provement. Epacadostat was purchased from MedChem Ex-
press. Stock solutions and prepared in DMSO for use in cell-
based assays.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al.,
2018), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2017/18 (Alexander et al., 2017).
Results
Tumour cell-derived IDO1 expression level does
not correlate with cancer patient survival
To date, it is still controversial whether tumour cell-derived
IDO1 expression level correlates with cancer patient survival
(Holmgaard et al., 2013). Using a Kaplan–Meier survival anal-
ysis (http://kmplot.com/analysis/), we failed to observe a sta-
tistically significant relationship between OS, PPS and DMFS
rates and tumour cell-derived IDO1 expression level in pa-
tients with various types of cancers such as lung, ovarian,
breast or gastric cancer (Figure 1A–H; Figure S2A–D). These
data suggest that targeting IDO1 as a therapeutic strategy
might be applicable to IDO1-expressing host-derived cells
but not tumour cells.
LW106 inhibited IDO1 enzyme activity but did
not affect tumour cell proliferation in vitro
To determine the in vitro inhibitory effect of LW106 on IDO1
enzyme activity, HeLa ovarian carcinoma cells were stimu-
lated with IFN-γ and applied to an enzyme activity assay. It
has been reported that expression level of IDO1 but not
IDO2 or tryptophan 2,3-dioxygenase (TDO2) was dra-
matically increased in the stimulated cells (Liu et al., 2010).
We observed that LW106 inhibited IDO1 enzyme activity
with an IC50 value of 1.57 μM while did not affect IDO1 pro-
tein expression level in the stimulated cells (Figure S3A, B).
Moreover, LW106 at doses ranging from 12.5 to 200 μM
did not affect proliferation of three types of tumour cells
with different expression levels of IDO1 (Figure S3C–E). It
has been reported that IDO1+ DCs can inhibit T-cell
proliferation/survival, which is believed to be responsible
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Figure 1
Tumour cell-derived IDO1 expression level does not correlate with cancer patient survival. Kaplan–Meier survival analysis of the relationship be-
tween survival rates and tumour cell-derived IDO1 expression level in patients with various types of cancers. (A, B) Relationship between OS (A)
and PPS (B) rates and IDO1 expression level in lung cancer patients. (C, D) Relationship between OS (C) and PPS (D) rates and IDO1 expression
level in ovarian cancer patients. (E–G) Relationship between OS (E), PPS (F) and DMFS (G) rates and IDO1 expression level in breast cancer pa-
tients. (H) Relationship between OS rate and IDO1 expression level in gastric cancer patients. Differences between two survival curves are mea-
sured by Log-Rank Test. n represents the number of patients.
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for IDO1-mediated tumour escape (Mellor et al., 2003). To
examine whether LW106 could reverse IDO1-mediated
T-cell suppression, IDO1+ mature DCs or IDO1 immature
DCs were co-cultured with purified lymphocytes in the pres-
ence of vehicle, LW106 or epacadostat. Co-cultured cells
were harvested, stained with anti-CD8 antibody and sub-
jected to FACS analysis. We found that IDO1 induction
strongly suppressed CD8+ T-cell proliferation/survival in
the co-culture system, and the suppression could be effec-
tively reversed by LW106 and epacadostat (Figure S4A, B).
LW106 dose-dependently inhibited the
outgrowth of IDO1-expressing tumour cells
inoculated in immunocompetent C57BL6 mice
but not athymic nude mice or Ido1/ mice
To further determine the inhibitory effect of LW106 on out-
growth of tumour cells in vivo, immunocompetent C57BL6
mice were challenged with IDO1-expressing Lewis lung carci-
noma cells and treated with various doses of LW106 or
epacadostat, an existing potent small molecule inhibitor of
IDO1 that is currently in clinical trial for cancer treatment.
We observed that LW106 dose-dependently inhibited tu-
mour growth, reducing tumour weights by 30, 54 and 68%
at 20, 40 and 80 mg·kg1 respectively (Figure 2A). Impor-
tantly, we failed to observe pathological changes in vital or-
gans (e.g. heart, liver, lung and kidney) of mice that received
LW106 treatment at 80 mg·kg1 (Figure S3A). Meanwhile,
epacadostat treatment at 80 mg·kg1 reduced tumour weight
by 51%, displaying a weaker antitumour efficacy as compared
with LW106 (Figure 2A). Similarly, a significant reduction in
tumour volumes was observed in LW106-treated mice rela-
tive to vehicle-treated mice (Figure 2B). A marked reduction
in kynurenine/tryptophan ratio was also detected in plasmas
and xenografts of LW106-treated mice (Figure 2C). However,
it should be noted that tryptophan depletion and GCN2
kinase activation may also play important roles in IDO1-
mediated tumour immune escape (Munn et al., 2005;
Eleftheriadis et al., 2014). Of note, both LW106- and
epacadostat-treated mice displayed markedly increased sur-
vival compared with vehicle-treated mice (Figure 2D). It
has been documented that IDO1 enzyme inhibitors require
intact T-cell function to suppress tumour growth in mice
(Liu et al., 2010). To evaluate the importance of T-cell-
dependent immunity to the antitumour effect of LW106,
athymic nude mice that are deficient in mature T cells were
challenged with Lewis tumour cells and tumour outgrowth
were monitored. In the context of these mice, LW106 treat-
ment at 80 mg·kg1 had no distinguished effect on tumour
outgrowth, suggesting that LW106 exerts its antitumour ef-
fect in a T-cell-dependent manner (Figure 2E). We further
applied Ido1/ (Ido1 knockout) mouse model to determine
whether IDO1 blockade in the inoculated tumour cells or
the host-derived cells is directly relevant to the mechanism
of antitumour effect of LW106. Interestingly, we found that
LW106 treatment at 80 mg·kg1 failed to suppress tumour
outgrowth in Ido1/ mice that were inoculated with
IDO1-expressing Lewis tumours, suggesting that LW106
inhibited tumour outgrowth via blocking activity of IDO1
expressed by the host-derived cells but not the inoculated
tumour cells (Figure 2F).
LW106 dose-dependently inhibited outgrowth
of IDO1-nonexpressing tumour cells inoculated
in C57BL6 mice but not athymic nude mice or
Ido1/ mice
We extended our studies to further evaluate LW106 treatment
in another widely used B16F10 melanoma tumour model
(IDO1 is undetectable in B16F10 cells). Again, we observed
that tumour weights were reduced by 29, 52 and 65% in mice
treated with LW106 at 20, 40 and 80 mg·kg1 respectively
(Figure 3A). We did not observe pathological changes in vital
organs (e.g. heart, liver, lung and kidney) ofmice that received
LW106 treatment at 80 mg·kg1 (Figure S5A, B). Epacadostat
displayed a weaker antitumour efficacy than LW106, with
a 50% reduction in tumour weight when administrated at
80 mg·kg1 (Figure 3A). Additionally, a substantial decrease
in tumour volumes was observed in LW106-treated mice rel-
ative to vehicle-treated mice (Figure 3B). LW106 treatment
at 80 mg·kg1 did not suppress outgrowth of B16F10 tu-
mours that were inoculated in athymic nude mice or
Ido1/ mice (Figure 3C, D), further support the notion that
T-cell immunity and IDO1 targeting in the host-derived
cells are essential for antitumour efficacy of LW106.
LW106 treatment enhanced the infiltration
and accumulation of Tcells in xenografted
tumours
Given that T-cell-dependent immunity is essential for
tumour-suppressive activity of LW106, we sought to study
the effector T cell and regulatory T cell compartments within
the Lewis and B16F10 tumours following LW106 treatment.
For this purpose, tumours were harvested 18 days after im-
plantation, and tumour-infiltrating lymphocytes were iso-
lated and subjected to FACS analysis. We observed a
significantly increased number of tumour-infiltrating CD8 ef-
fector T cells (CD8+CD45+) in mice treated with LW106 as
compared with vehicle-treated mice (Figure 4A; Figure S6A).
LW106 treatment also increased infiltration of proliferative
CD8 effector T cells within the xenografted tumours, as mea-
sured by expression of Ki67, a widely used cell proliferating
marker (Figure 4B). By contrast, infiltration of regulatory T
cells (CD4+Foxp3+CD45+) was robustly reduced in LW106-
treated mice relative to vehicle-treated mice (Figure 4C). A
dramatic decrease in the percentage of proliferative regula-
tory T cells was observed within xenografted tumours of
LW106-treated mice (Figure 4D; Figure S6B). Intratumoural
ratios of CD4 effector T cells (CD4+Foxp3CD45+) to regula-
tory T cells were markedly elevated in LW106-treated mice
as compared with vehicle-treated mice (Figure 4E; Figure
S6C). Additionally, immunofluorescence analysis further re-
vealed a robustly increased infiltration of proliferative CD8
effector T cells (Ki67+CD8+) within xenografted tumours of
LW106-treated mice (Figure 4F; Figure S6D).
LW106 treatment enhanced accumulation of
splenic Tcells in Lewis tumour-bearing mice
Because spleen serves as an important reservoir for lympho-
cytes that can be recruited to the tumour sites and directly in-
volve in antitumour immunity, we therefore sought to study
the effector T cell and regulatory T cell compartments in the
spleens of tumour-bearing mice. We observed markedly
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Figure 2
Lewis tumour outgrowth suppression by LW106 depends on T cells and IDO1 targeting. Mice were administered the indicated compounds, i.p.
daily, at day 6 following s.c. challenge with 6 × 105 Lewis tumour cells. (A) Tumour weights in immunocompetent mice (n = 6 mice, each). (B)
Individual tumour growth in immunocompetent mice (n = 6 mice, each). (C) Ratio of tryptophan to kynurenine concentration in plasma and
xenografted tumours from immunocompetent mice (n = 6 mice, each). (D) Kaplan–Meier survival curves for tumour-bearing mice that were
treated with vehicle, LW106 and epacadostat (n = 6 mice, each). (E, F) Individual tumour growth in BALB/c nude mice (E) and Ido1/ mice (F)
(n = 5 mice, each). Statistical significance was evaluated by two-way ANOVA test (A, B, C, E and F; *P < 0.05; #P < 0.05) and Log-Rank test (D).
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enlarged spleens in mice that received LW106 treatment as
compared with epacadostat- or vehicle-treated mice
(Figure 5A, B). Importantly, H&E staining of spleens from
LW106-treated mice revealed no distinguished pathological
changes (Figure 5C). Flow cytometry analysis of splenocytes
revealed a higher percentage of CD8 effector T cells in the
spleens of LW106-treated mice as compared to vehicle-
treated mice (Figure 5D). Furthermore, LW106 treatment sig-
nificantly increased the percentage of proliferative CD8 and
CD4 effector T cells in tandem with a marked reduction in
the percentage of proliferative regulatory T cells in the
spleens (Figure 5E–G). Taken together, these results suggest
that LW106 treatment increased the number of splenic effec-
tor T cells that can be recruited to the tumour sites and func-
tion there.
LW106 treatment resulted in impaired
proliferation and survival of tumour cells in
tandem with reduced recruitment of
non-haemopoietic stromal cells and deposition
of ECM in the TME
The data above had shown that tumour outgrowth was
significantly inhibited in LW106-treated mice. We next
Figure 3
B16F10 melanoma outgrowth suppression by LW106 is dependent on T cells and IDO1. Mice were administered the indicated compounds, i.p.
daily, at day 6 following s.c. challenge with 2 × 105 B16F10 melanoma cells. (A) Tumour weights in immunocompetent mice (n = 6 mice, each).
(B) Individual tumour growth in immunocompetent mice (n = 6mice, each). (C, D) Individual tumour growth in BALB/c nudemice (C) and Ido1/
mice (D) (n = 5 mice, each). Statistical significance was evaluated by two-way ANOVA test (*P < 0.05; #P < 0.05).
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Figure 4
LW106 treatment enhances the infiltration and accumulation of T cells in xenografted tumours. Lewis tumours from vehicle-, LW106- and
epacadostat-treated mice were harvested 18 days after tumour inoculation and subjected to FACS and immunofluorescent analyses. (A) Rep-
resentative dot plots and percentage of CD8+ effector T cells of total CD45+ cells for vehicle-, LW106- and epacadostat-treated mice (n = 5
mice, each). (B) Representative dot plots and percentage of CD8+ effector T cells expressing Ki67 for indicated mice, as shown in (A). (C) Per-
centage of CD4+Foxp3+ regulatory T cells of total CD45+ cells for indicated mice, as shown in (A). (D) Percentage of CD4+Foxp3+ regulatory T
cells expressing Ki67 for indicated mice, as shown in (A). (E) Ratio of CD4+Foxp3 effector T cells to CD4+Foxp3+ regulatory T cells in tumours
of indicated mice, as shown in (A). (F) Representative immunofluorescent images (left panels; images are representative of images from five
mice) and percentage of CD8+ T cells expressing Ki67 for tumours of indicated mice (right panel; 1000–2000 cells were counted in 10 random
fields from each slide). Arrow head denotes Ki67+CD8+ cells. Statistical significance was evaluated by two-way ANOVA test (*P < 0.05; N.S.,
not significant).
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Figure 5
LW106 treatment enhances the accumulation of splenic T cells in Lewis tumour-bearing mice. Spleens from Lewis tumour-bearing mice
that were treated with vehicle, LW106 and epacadostat were harvested and subjected to FACS and histological analyses. (A) Gross exam-
ination of spleens from tumour-bearing mice that were treated with the indicated compounds (n = 6 mice, each). (B) Spleen weights in
tumour-bearing mice as shown in (A). (C) H&E staining of spleens as shown in (A). (D) Representative dot plots and percentage of CD8+
effector T cells of total CD45+ cells for spleens of tumour-bearing mice that were treated with the indicated compounds (n = 6 mice in
three pools, each). (E) Representative dot plots and percentage of CD8+ effector T cells expressing Ki67 for spleens of tumour-bearing
mice as shown in (D). (F, G) Percentages of CD4+Foxp3 effector T cells (F) and CD4+Foxp3+ regulatory T cells (G) expressing Ki67 for
spleens of tumour-bearing mice as shown in (D). Statistical significance was evaluated by two-way ANOVA test (*P < 0.05; N.S., not
significant).
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Figure 6
LW106 treatment results in impaired proliferation and survival of Lewis tumour cells in tandem with reduced recruitment of tumour-associated
stromal cells and accumulation of extracellular matrix. Lewis xenografted tumours from vehicle-, LW106- and epacadostat-treated mice were har-
vested 18 days after tumour challenge and analysed by immunohistochemistry. (A) Representative immunohistochemical images (left panels; im-
ages are representative of images from six mice) and percentages of Ki67-, phospho-histone H3- and cleaved caspase 3-positive cells for tumours
of indicated mice (right panels; 1000–2000 cells were counted in 10 random fields of each slide). (B) Representative immunofluorescent images
(left panels; images are representative of images from six mice), percentage of Ki67-positive cells (1st row at right panels; 1000–2000 cells were
counted in 10 random fields of each slide) and relative fluorescent intensities of type I collagen, CD31 and α-SMA (rest rows at right panels; relative
fluorescent intensities were calculated in 10 random fields of each slide) for tumours of indicated mice (n = 6 mice, each). Statistical significance
was evaluated by two-way ANOVA test (*P < 0.05; #P < 0.05; N.S., not significant).
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sought to determine whether LW106 treatment could affect
the proliferation and survival of tumour cells within Lewis
and B16F10 tumours. For this purpose, we performed im-
munohistochemical staining of Ki67 (a proliferative cell
marker), phospho-Histone H3 (a mitotic cell marker) and
cleaved caspase 3 (an apoptotic cell marker) in the
xenografted tumours. We found that the percentages of
proliferative and mitotic cells were markedly decreased in
tumours of LW106-treated mice relative to vehicle-treated
mice (Figure 6A; Figure S7A). By contrast, the percentage
of apoptotic cells was significantly increased in tumours
of LW106-treated mice (Figure 6A; Figure S7A). A reduced
number of cytokeratin-14 (K14)-positive tumour cells (i.e.
invasive tumour cells) was also observed in tumours of
LW106-treated mice (Figure 6B). These data suggest that
LW106 treatment decreases the proliferation, survival and
invasiveness of tumour cells, thus suppressing tumour
outgrowth.
The relationship between the stroma and tumour-
infiltrating lymphocytes remains largely uncharacterized
(Turley et al., 2015). Emerging evidences have suggested
that the stromal compartments (e.g. CAFs, ECs as well as
ECM) can shape antitumour immunity and responsiveness
to immunotherapy (Turley et al., 2015). We therefore
sought to determine whether LW106 treatment could af-
fect the recruitment of non-haematopoietic stromal cells
and the deposition of stroma-derived ECM in the TME,
which may contribute to its antitumour effect. Immunohis-
tochemical assay showed that type I collagen expression
level was significantly decreased in tumours of LW106-
treated mice, indicating a reduced ECM deposition in the
tumours following LW106 treatment (Figure 6B; Figure
S7B). We further observed that the percentages of CD31-
positive cells (i.e. ECs) and α-SMA-positive cells (i.e. CAFs)
were substantially reduced in tumours of LW106-treated
mice as compared with vehicle-treated mice (Figure 6B;
Figure S7B). These data illustrated that targeting IDO1 in
host-derived cells by LW106 inhibited recruitment of
non-haematopoietic stromal cells and deposition of ECM,
which could generate a tumour-suppressive micro-
environment within the tumours and thus suppress
tumour outgrowth.
LW106 treatment inhibited enrichment of
CSCs in xenografted tumours
CSCs, a population tumour cells that possess the defining fea-
tures of clonogenicity and self-renewal, are proposed to have
a critical role in tumour progression, metastasis and drug re-
sistance (Codony-Servat et al., 2016; Hardavella et al., 2016;
Ni et al., 2016). CSCs in human lung tumours were identified
using a list of markers such as CD133, CD44 and ALDH1
(Codony-Servat et al., 2016; Hardavella et al., 2016). To test
whether these markers could also be used for identification
of CSCs in Lewis xenografted tumours, we sorted tumour cells
using FACS with these markers and performed in vitro
tumoursphere assays. Although we could not detect CD133
expression in the xenografted tumours (data not shown),
we indeed observed that ALDH+ or CD44+ALDH+ cells pos-
sessed the potentials to form tumoursphere (Figure 7A).
These results suggest that both CD44 and ALDH1 can be used
as markers for identification of CSCs in Lewis xenografted tu-
mours. We further found that xenografted tumours of
LW106-treated mice displayed markedly reduced numbers
of CD44+, ALDH+ or CD44+ALDH+ cells as compared with
vehicle-treated mice (Figure 7B), which may be attributed to
the regression of tumours observed in LW106-treated mice
(Figure 2A).
Discussion
Inhibition of IDO1 is a very promising area of cancer immu-
notherapy. Three small-molecule inhibitors of IDO1, 1-MT,
NLG919 and epacadostat, are currently in clinical trials for
treatment of various types of cancer including NSCLC, ovar-
ian cancer and melanoma (Cady and Sono, 1991; Liu et al.,
2010; Jackson et al., 2013). These compounds possess poten-
tial immunomodulating and antineoplastic activities by
inhibiting IDO1 enzyme activity in the tumour cells and
host-derived immune cells such as DCs and macrophages
(Cady and Sono, 1991; Liu et al., 2010; Jackson et al., 2013).
In the present study, we have discovered LW106 as a structur-
ally novel, selective and potent small-molecule inhibitor of
IDO1. In comparison with epacadostat, LW106 showed a
weaker in vitro inhibition on IDO1 enzyme activity when
assayed in IFN-γ-stimulated HeLa cells but indeed displayed
a stronger antitumour efficacy in mice bearing xenografted
tumours. It is unlikely that the antitumour activity of
LW106 is due to the ‘off-target’ effect as the compound does
not suppress tumour outgrowth in Ido1/ mice. A possible
explanation for the distinguished inhibition performed by
LW106 in vitro versus in vivo is that LW106 might be metabo-
lized into potential metabolite(s) in vivo that can inhibit
IDO1 enzyme activity more efficiently than LW106 itself,
and further work is required to identify and synthesize the
potential metabolite(s) and evaluate their antitumour
efficacy. Nevertheless, LW106 can be considered as a potent
and selective inhibitor of IDO1 since treatment with the
compound causes a strong tumour regression in IDO1-
intact mice but fails to inhibit tumour outgrowth in IDO1-
deficient mice.
Inhibition of IDO1 enzyme activity in tumour cells ap-
pears not to affect cell growth in vitro as tumour cells grow
normally when treated with LW106 at a concentration of
over 100-fold higher than EC50. The inhibitory effect of
LW106 on tumour outgrowth in vivo is related to IDO1 ex-
pression by host-derived immune cells but not tumour cells
since LW106 administrated in vivo display a comparable in-
hibitory effect on proliferation of IDO1-expressing xeno-
grafts versus IDO1-nonexpressing xenografts. In addition,
Kaplan–Meier survival analysis reveals that the mRNA levels
of IDO1 expressed by tumour cells do not correlate with the
survivals in patients with various types of cancers such as
lung, ovarian, breast or gastric cancer. Hence, it is reasonable
to propose that IDO1 expression by host-derived cells rather
than tumour cells can be used as a predictive marker for re-
sponse to therapy with LW106 as well as other selective in-
hibitors of IDO1 such as NLG919 (Jackson et al., 2013) and
epacadostat (Liu et al., 2010) and that such immunotherapy
can also be beneficial for patients with undetectable IDO1 ex-
pression in tumour cells.
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Emerging evidence suggests that the stromal compart-
ment in the TME may hinder antitumour immune response
via actively interacting with the surrounding immune cells
(Joyce and Pollard, 2009; Turley et al., 2015). For instance,
non-haematopoietic stromal cells such as CAFs and ECs
express numerous surface and secreted molecules to directly
suppress CD4+ and CD8+ effector T cells and activate suppres-
sive myeloid cells and CD4+ regulatory T cells (Castermans
and Griffioen, 2007; Buckanovich et al., 2008; Joyce and
Pollard, 2009; Tan et al., 2011; Feig et al., 2013). The stroma-
Figure 7
LW106 treatment inhibits cancer stem cell enrichment in Lewis tumours. Tumours from vehicle-, LW106- and epacadostat-treated mice were har-
vested 18 days after tumour challenge and subjected to FACS and tumoursphere assays. (A) Representative tumoursphere images (left panels; im-
ages are representative of images from six xenografted tumours in three pools) and number of tumourspheres formed by FACS-sorted
CD44ALDH, ALDH+ and CD44+ALDH+ tumour cells of Lewis xenografts (right panels; n = 3 independent experiments). (B) Representative
dot plots (left panels; plots are representative of plots from six mice in three pools) and percentages of CD44+, ALDH+ and CD44+ALDH+ cancer
stem cells for tumours of indicated mice (right panels; n = 6 mice in three pools). Statistical significance was evaluated by two-way ANOVA
test (*P < 0.05; #P < 0.05).
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derived ECM in the TME may also suppress antitumour
immune response by limiting T cell motility and localization
(Joyce and Pollard, 2009; Provenzano et al., 2012; Salmon
et al., 2012; Caruana et al., 2015). Of note, immune cells in-
cluding regulatory T cells, cancer-associated macrophages
(CAMs; F4/80+ cells) and suppressive myeloid cells also se-
crete numerous molecules, to directly support activation
and survival of stromal cells (Joyce and Pollard, 2009; Beatty
et al., 2011; Lu et al., 2011; Coussens et al., 2013; Turley
et al., 2015). In the current study, we have discovered that
LW106 profoundly inhibits stromal cell recruitment and
ECM deposition in the TME, which in turn causes an im-
paired crosstalk between stromal compartment and T cells,
thus promoting T cell immune response to tumours. On the
other hand, our data suggest that targeting IDO1 in host-
derived cells by LW106 strongly suppresses infiltration of
CD4+Foxp3+ regulatory T cells and F4/80+ CAMs (data not
shown), which consequently results in an impaired
immune-stroma interaction, thus limiting recruitment, acti-
vation and survival of stromal cells in the TME. Further work
is required to define the precise mechanisms by which
LW106 inhibits recruitment, activation and survival of non-
haematopoietic stromal cells in the TME. In addition to the
immunomodulatory role, stromal compartment in the TME
may also have a critical role in controlling CSC expansion
(Buckanovich et al., 2008; Joyce and Pollard, 2009). Herein,
we demonstrate that the expansion of CSCs is strongly sup-
pressed in tumours of LW106-treated mice, suggesting that
the inhibitory effect of LW106 on tumour growth and
chemoresistance can, at least in part, be attributed to reduced
CSC enrichment in the TME.
In conclusion, the data presented here suggest that
LW106 inhibits tumour growth by limiting stroma-immune
crosstalk and CSC enrichment in the TME and that LW106
can be further developed as a potential immunotherapeutic
agent used in combination with immune checkpoint inhibi-
tors and (or) chemotherapeutic drugs for cancer treatment.
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Figure S1 Chemical structure of LW106. Dashed area repre-
sents structural modification of lead compound 62.
Figure S2 Tumor cell-derived IDO1 expression level does not
correlate with survival of two subtypes of lung cancer pa-
tients. Kaplan–Meier survival analysis of the relationship be-
tween survival rates and tumor cell-derived IDO1 expression
level in two subtypes of lung cancer patients. (A, B) Relation-
ship between overall survival (OS) rate and IDO1 expression
level in lung adenocarcinoma (A) and squamous (B) patients.
(C, D) Relationship between post-progression survival (PPS)
rate and IDO1 expression level in lung adenocarcinoma (C)
and squamous (D) patients. Differences between two survival
curves are measured by Log-Rank Test. n represents the num-
ber of patients.
Figure S3 LW106 treatment inhibits IDO1 enzyme activity
but does not affect tumor cell proliferation in vitro. (A) Inhibi-
tion rate of kynurenine (Kyn) for IFN-γ- stimulated HeLa cells
that were treated with indicated concentrations of LW106 for
48 hrs (n = 3 independent experiments). (B) Western blot
analysis of IDO1 protein levels for IFN-γ-stimulated HeLa
cells that were treated with indicated compounds (results
are representatives of three experiments). (C) Survival rate
of indicated tumor cells that were treated with increasing
doses of LW106. Cells were stained with trypan blue dye
and the staining exclusive cells (i.e. live cells) were counted
under light microscope. n = 3 independent experiments. (D)
Representative images of cells as described in C. (E) Western
blot analysis of IDO1 protein levels for B16F10 and Lewis cells
(results are representatives of three experiments).
Figure S4 LW106 treatment reverses CD8+ T-cell suppres-
sion mediated by IDO1+ mature DCs. IDO1- immature
DCs were treated with 50 ng/ml hIFN-γ and 1 μg/ml LPS
for 2 days, and the obtained IDO1+ mature DCs or IDO1-
immature DCs were cocultured with purified lymphocytes
in the presence of vehicle, LW106 or epacadostat for
additional 2 days. Co-cultured cells were harvested, stained
with anti-CD8 antibody and subjected to FACS analysis. (A)
Representative plot of FACS analysis. (B) Percentage of CD8+ T
cells in the co-culture system as described in A. n = 3 indepen-
dent experiments. Statistical significance was evaluated by
two-way ANOVA test (*P < 0.05; **P < 0.01).
Figure S5 LW106 treatment does not induce histological
change in tumorbearing mice. (A, B) H.E. staining of vital or-
gans from LW106-trated mice bearing with Lewis tumor cells
(A) and B16F10 melanoma cells (B). Images are representative
of images from six mice.
Figure S6 LW106 treatment enhances infiltration and ac-
cumulation of T cells in B16F10 tumors. B16F10 xenografts
from vehicle-, LW106- and epacadostat-treated mice were
harvested 18 days after tumor challenge and subjected to
FACS and immunofluorescent analyses. (A) Representative
dot plots and percentage of CD8+ effector T cells of total
CD45+ cells for vehicle-, LW106- and epacadostat-treated
mice (n = 5 mice, each). (B) Percentage of CD4 + Foxp3+
regulatory T cells expressing Ki67 for indicated mice as
shown in A. (C) Ratio of CD4 + Foxp3- effector T cells to
CD4 + Foxp3+ regulatory T cells in tumors of indicated
mice as shown in A. (D) Representative immunofluorescent
images (left panels; images are representative of images from
five mice) and percentage of CD8+ T cells expressing Ki67
for tumors of indicated mice (right panel; 1000 ~ 2000 cells
were counted in 10 random fields of each slide). Arrow
head denotes Ki67 + CD8+ cells. Statistical significance
was evaluated by two-way ANOVA test (*P < 0.05;
**P < 0.01; #P < 0.05; N.S., not significant).
Figure S7 LW106 treatment results in impaired proliferation
and survival of B16F10 melanoma cells in tandem with re-
duced recruitment of tumor-associated stromal cells and de-
position of extracellular matrix. B16F10 xenografted tumors
from vehicle-, LW106- and epacadostat-treated mice were
harvested 18 days after tumor challenge and analyzed by im-
munohistochemistry. (A) Representative immunohistochem-
ical images (left panels; images are representative of images
from six mice) and percentages of Ki67-, phospho-histone
H3- and cleaved caspase 3-positive cells for tumors of indi-
cated mice (right panels; 1000 ~ 2000 cells were counted in
10 random fields of each slide). (B) Representative immuno-
fluorescent images (left panels; images are representative of
images from six mice) and relative fluorescent intensities of
type I collagen, CD31 and α-SMA (right panels; relative fluores-
cent intensities were calculated in 10 random fields of each
slide) for tumors of indicated mice (n = 6 mice, each).
Statistical significance was evaluated by two-way ANOVA test
(*P < 0.05; **P < 0.01; ***P < 0.001; N.S., not significant).
Targeting IDO1 limits stroma-immune crosstalk
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